Current Value
$11.101 Year Return
Current Value
$11.101 Year Return
Finnhub
#64919 Characterization of ORKA-002, a Novel Extended Half-life Monoclonal Antibody Targeting IL-17A/F for the Treatment of Psoriasis and Other Indications ...
Finnhub
Half-life in non-human primates of more than 30 days, over three times longer than bimekizumab and expected to support a dose interval of two to three times per year Equivalent potency to...
Finnhub
ORKA-001, targeting IL-23p19, Phase 1 trial ongoing, with pharmacokinetic data expected in 2H 2025 ORKA-001 Phase 2a initiation expected in 2H 2025, with efficacy readout in 2H 2026 that provides...
Yahoo
MENLO PARK, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis, today announced presentations at the following upcoming investor conferences: TD Cowen’s 45th Annual Health Care ConferenceDate: Tuesday, March 4th, 2025Time: 10:30AM ET Leerink Global Healthcare ConferenceDate: Wednesday, Marc
Yahoo
Oruka Therapeutics (ORKA) announced that it has initiated dosing of healthy volunteers in its first clinical trial of ORKA-001, the Company’s novel, subcutaneously administered, half-life extended monoclonal antibody targeting IL-23p19. Pharmacokinetic and safety data from healthy volunteers anticipated in the second half of 2025. On track to initiate a proof-of-concept study in psoriasis in the second half of 2025, with initial efficacy data expected in the second half of 2026. Preclinical data
Yahoo
Pharmacokinetic and safety data from healthy volunteers anticipated in the second half of 2025 On track to initiate a proof-of-concept study in psoriasis in the second half of 2025, with initial efficacy data expected in the second half of 2026 Preclinical data with ORKA-001 demonstrate the potential for once- or twice-yearly dosing, a significant improvement over standard of care MENLO PARK, Calif., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a biotechno
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
VNDA | 39.03% | $290.41M | +30.71% | 0.00% |
SNDL | 32.11% | $400.91M | +7.86% | 0.00% |
ABUS | 31.56% | $625.32M | +25.95% | 0.00% |
GHM | 28.64% | $350.09M | +29.89% | 0.00% |
AG | 28.08% | $3.23B | +18.44% | 0.27% |
FSM | 27.66% | $1.73B | +64.53% | 0.00% |
TLRY | 26.24% | $571.88M | -64.75% | 0.00% |
PLAY | 26.03% | $669.95M | -72.24% | 0.00% |
GE | 25.75% | $211.56B | +46.34% | 0.75% |
TGS | 25.73% | $1.90B | +113.35% | 0.00% |
WT | 24.96% | $1.26B | -4.26% | 1.42% |
PARA | 24.28% | $7.84B | +4.28% | 1.70% |
GRWG | 24.12% | $62.21M | -47.50% | 0.00% |
NOK | 23.67% | $28.64B | +44.44% | 2.60% |
DYN | 23.58% | $1.36B | -56.95% | 0.00% |
NNE | 23.41% | $1.12B | +656.50% | 0.00% |
JEF | 22.93% | $11.61B | +29.64% | 2.49% |
NOAH | 22.84% | $740.69M | +21.31% | 9.56% |
BPT | 22.15% | $12.43M | -75.79% | 0.00% |
FC | 22.06% | $403.79M | -22.04% | 0.00% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
FE | -<0.01% | $22.97B | +4.95% | 4.27% |
WIX | 0.01% | $9.60B | +27.31% | 0.00% |
HQY | 0.02% | $8.44B | +19.61% | 0.00% |
ELS | -0.02% | $12.82B | +2.48% | 2.85% |
CTMX | -0.03% | $52.03M | -68.62% | 0.00% |
CWT | 0.04% | $2.83B | +2.64% | 2.41% |
UVV | 0.04% | $1.37B | +8.76% | 5.82% |
PRI | 0.05% | $9.49B | +15.59% | 1.26% |
BBVA | -0.05% | $82.55B | +25.90% | 5.08% |
AMWL | 0.06% | $124.26M | -55.30% | 0.00% |
VNT | -0.06% | $4.93B | -23.25% | 0.30% |
AMT | -0.07% | $98.60B | +6.89% | 3.05% |
WCN | -0.07% | $47.82B | +8.40% | 0.65% |
PHG | 0.08% | $24.74B | +31.36% | 0.00% |
CVGW | -0.09% | $412.92M | -19.79% | 2.58% |
EXPE | 0.10% | $20.89B | +21.46% | 0.24% |
IMMP | 0.10% | $259.10M | -25.52% | 0.00% |
ASTH | -0.10% | $1.44B | -26.43% | 0.00% |
ETR | -0.10% | $36.58B | +66.71% | 4.80% |
NTIC | 0.10% | $106.73M | -19.33% | 2.48% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
VIXY | -14.51% | $195.31M | 0.85% |
TAIL | -12.83% | $81.50M | 0.59% |
BTAL | -10.77% | $392.59M | 1.43% |
FLDR | -10.22% | $754.32M | 0.15% |
BIL | -9.99% | $41.72B | 0.1356% |
UUP | -9.26% | $319.56M | 0.77% |
UNG | -9.04% | $435.14M | 1.06% |
BSSX | -8.11% | $73.97M | 0.18% |
USDU | -8.04% | $279.86M | 0.5% |
BNO | -7.38% | $89.45M | 1% |
OWNS | -6.93% | $133.39M | 0.3% |
DBE | -6.86% | $53.72M | 0.77% |
NFLT | -6.80% | $242.80M | 0.5% |
TFLO | -6.67% | $6.75B | 0.15% |
USO | -6.50% | $839.47M | 0.6% |
JMST | -6.35% | $3.52B | 0.18% |
SHYD | -6.12% | $319.95M | 0.35% |
XBIL | -5.91% | $705.62M | 0.15% |
DBO | -5.50% | $188.24M | 0.77% |
CANE | -5.49% | $12.06M | 0.29% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
BOXX | 0.01% | $5.53B | 0.1949% |
XHLF | -0.07% | $1.06B | 0.03% |
SPSK | 0.10% | $293.22M | 0.5% |
KXI | 0.11% | $722.24M | 0.41% |
GNMA | -0.15% | $355.91M | 0.1% |
IBTF | -0.29% | $2.22B | 0.07% |
ULST | -0.30% | $579.50M | 0.2% |
FXI | 0.31% | $7.88B | 0.74% |
GXC | 0.31% | $475.86M | 0.59% |
EUSB | -0.32% | $681.72M | 0.12% |
FLRT | 0.32% | $513.19M | 0.6% |
EWZS | 0.33% | $119.71M | 0.6% |
CARY | -0.38% | $347.36M | 0.8% |
XONE | -0.41% | $620.20M | 0.03% |
CMDY | 0.44% | $303.92M | 0.28% |
MCHI | 0.46% | $6.38B | 0.59% |
PDBC | -0.52% | $4.78B | 0.59% |
BCD | 0.53% | $236.83M | 0.3% |
STXT | 0.56% | $131.84M | 0.49% |
HYZD | -0.57% | $180.70M | 0.43% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
ULTA | -21.92% | $16.58B | -33.30% | 0.00% |
BIRK | -17.55% | $8.20B | -7.33% | 0.00% |
DG | -13.37% | $17.38B | -48.00% | 2.96% |
DLTR | -13.19% | $13.88B | -49.33% | 0.00% |
CBOE | -12.33% | $22.40B | +16.58% | 1.13% |
RPRX | -12.14% | $14.20B | +8.91% | 2.59% |
CNNE | -11.57% | $1.03B | -25.64% | 2.22% |
TR | -11.22% | $2.27B | +2.71% | 1.14% |
BNED | -10.54% | $337.13M | -84.11% | 0.00% |
JNJ | -10.31% | $391.98B | +2.93% | 3.05% |
COTY | -10.21% | $4.80B | -55.35% | 0.00% |
HRL | -9.95% | $16.24B | -13.47% | 3.84% |
PG | -9.79% | $393.86B | +4.08% | 2.39% |
WBA | -9.41% | $9.71B | -46.06% | 6.68% |
MNST | -9.30% | $53.61B | -8.87% | 0.00% |
CPB | -9.20% | $11.46B | -10.04% | 3.90% |
DDS | -9.11% | $5.68B | -11.45% | 0.28% |
CHD | -9.11% | $26.84B | +4.56% | 1.05% |
K | -8.85% | $28.39B | +53.53% | 2.76% |
AGL | -8.64% | $1.67B | -23.87% | 0.00% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
RSPA | 32.15% | $272.02M | 0% |
QQA | 24.97% | $161.30M | 0% |
CPRJ | 24.92% | $48.94M | 0.69% |
BTC | 21.66% | $3.28B | 0.15% |
XBI | 21.62% | $5.61B | 0.35% |
HEQT | 21.51% | $392.51M | 0.44% |
PTH | 21.23% | $109.34M | 0.6% |
SLVP | 20.16% | $253.48M | 0.39% |
ETH | 20.12% | $1.29B | 0% |
XSD | 20.11% | $1.11B | 0.35% |
EZET | 20.08% | $21.77M | 0% |
IWO | 19.92% | $10.63B | 0.24% |
ETHW | 19.77% | $175.81M | 0% |
ETHA | 19.77% | $2.31B | 0.25% |
ETHV | 19.75% | $87.32M | 0% |
FETH | 19.74% | $755.56M | 0.25% |
CETH | 19.74% | $7.85M | 0% |
EFAA | 19.72% | $93.45M | 0% |
GRID | 19.65% | $2.15B | 0.57% |
QETH | 19.59% | $15.21M | 0.25% |